Shanghai Labway Clinical Laboratory Co

Shanghai Labway Clinical Laboratory Co FCF Margin

The Free Cash Flow Margin of Shanghai Labway Clinical Laboratory Co (301060.SZ) as of Nov 3, 2026 is 14.53 %. In the previous year, Free Cash Flow Margin was 8.02 % — a change of 81.17% (higher).

FCF Margin

14.53 %

YoY

81.17%

Last updated:

Free Cash Flow Margin of Shanghai Labway Clinical Laboratory Co is 2025 14.53 % . Free Cash Flow Margin of Shanghai Labway Clinical Laboratory Co was 2024 8.02 % . It decreases by 81.17% higher compared to the previous year.

The Shanghai Labway Clinical Laboratory Co FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
10.59 CNY
Jan 1, 2019
2.70 CNY
Jan 1, 2020
9.96 CNY
Jan 1, 2021
5.88 CNY
Jan 1, 2022
-3.47 CNY
Jan 1, 2023
8.85 CNY
Jan 1, 2024
8.02 CNY
Jan 1, 2025
14.53 CNY
The Shanghai Labway Clinical Laboratory Co FCF Margin history
YEARFCF MarginYoY
14.53 %+81.17%
8.02 %-9.35%
8.85 %-354.57%
-3.47 %-159.06%
5.88 %-40.93%
9.96 %+269.56%
2.70 %-74.54%
10.59 %-143.23%
-24.49 %+158.95%
-9.46 %-254.50%
6.12 %-133.91%
-18.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Labway Clinical Laboratory Co Stock analysis

What does Shanghai Labway Clinical Laboratory Co do? Shanghai Labway Clinical Laboratory Co., Ltd. generates revenue through medical and pathological examination services, including pathological diagnosis, molecular examination, biochemical examination, immune examination, microbial examination, clinical basic examination, and physical and chemical examination. The company also sells in vitro diagnostic instruments, reagents, and related accessories and consumables. Its primary customers are healthcare providers and medical institutions requiring diagnostic services and diagnostic products. The business segments are medical testing services and in vitro diagnostic product sales. The company's medical testing services cater to hospitals and clinics seeking comprehensive diagnostic solutions, while the in vitro diagnostic product sales target healthcare facilities needing equipment and supplies for laboratory operations. These services and products are provided to clients across China, focusing on the healthcare sector's demand for accurate and timely diagnostic capabilities. Shanghai Labway's revenue streams are derived from both service fees for examinations and sales of diagnostic instruments and reagents. The company's offerings align with the growing need for advanced medical diagnostics in China's expanding healthcare market, serving a broad client base within the medical industry. Shanghai Labway Clinical Laboratory Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Labway Clinical Laboratory Co stock

Free Cash Flow Margin of Shanghai Labway Clinical Laboratory Co is 14.53 % in 2025.

Free Cash Flow Margin of Shanghai Labway Clinical Laboratory Co changed from 8.02 % to 14.53 %, representing a 81.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Shanghai Labway Clinical Laboratory Co since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Shanghai Labway Clinical Laboratory Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Shanghai Labway Clinical Laboratory Co

All Key Metrics — Shanghai Labway Clinical Laboratory Co